Rejoinder
Clin Trials
.
2017 Apr;14(2):126-127.
doi: 10.1177/1740774516688917.
Epub 2017 Jan 31.
Authors
Thomas R Fleming
1
,
David L DeMets
2
,
Matthew T Roe
3
,
Janet Wittes
4
,
Karim A Calis
5
6
,
Amit N Vora
3
,
Alan Meisel
7
,
Raymond P Bain
8
,
Marvin A Konstam
9
,
Michael J Pencina
3
,
David J Gordon
10
,
Kenneth W Mahaffey
11
,
Charles H Hennekens
12
,
James D Neaton
13
,
Gail D Pearson
10
,
Tomas Lg Andersson
14
,
Marc A Pfeffer
15
,
Susan S Ellenberg
16
Affiliations
1
1 Department of Biostatistics, University of Washington, Seattle, WA, USA.
2
2 University of Wisconsin, Madison, WI, USA.
3
3 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
4
4 Statistics Collaborative, Inc., Washington, DC, USA.
5
5 Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.
6
6 National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA.
7
7 University of Pittsburgh, Pittsburgh, PA, USA.
8
8 Merck Research Laboratories, North Wales, PA, USA.
9
9 Tufts Medical Center, Boston, MA, USA.
10
10 National Heart, Lung and Blood Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
11
11 Stanford University School of Medicine, Stanford, CA, USA.
12
12 Florida Atlantic University, Boca Raton, FL, USA.
13
13 University of Minnesota, Minneapolis, MN, USA.
14
14 AstraZeneca, Mölndal, Sweden.
15
15 Brigham and Women's Hospital, Boston, MA, USA.
16
16 University of Pennsylvania, Philadelphia, PA, USA.
PMID:
28135837
PMCID:
PMC5376229
DOI:
10.1177/1740774516688917
No abstract available
Publication types
Kommentar
MeSH terms
Advisory Committees*
Clinical Trials Data Monitoring Committees*
Research Design
Grants and funding
R37 AI029168/AI/NIAID NIH HHS/United States